Ephedrine dilemma highlights DSHEA's faults, Food Advisory Committee members say.
This article was originally published in The Tan Sheet
EPHEDRINE ALKALOID SAFETY ASSURANCE DIFFICULTIES HIGHLIGHT DSHEA's LIMITATIONS, committee member Bruce Chassy, PhD, University of Illinois at Urbana, suggested at an Aug. 27-28 meeting of FDA's Food Advisory Committee in Washington, D.C. The Dietary Supplement Health & Education Act is "from our normal perspective of regulating drugs, backwards," Chassy asserted. Under the act, "we put [a dietary supplement] on the market, we collect adverse reactions and when we've got enough of them, we take a look at them," he said.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC